Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002864 · ClinicalTrials.gov registry record · Phase 3
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
A Phase 3 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 667
- Enrollment target
NCT00002864 is a Phase 3 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 667 participants.
The verdict
NCT00002864, a Phase 3 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 667 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen with or without octreotide may fight breast cancer by blocking the uptake of estrogen. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without octreotide in treating postmenopausal women who have stage I, stage II, or stage III breast cancer.
Interventions
- DRUG tamoxifen citrate
- DRUG octreotide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 667 participants |
| Start Date | 1996-09-24 |
| Est. Completion | 2010-04-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002864
The ClinicalTrials.gov registry entry for NCT00002864 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 667 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tamoxifen citrate is the first listed.
NCT00002864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002864 about?
NCT00002864 is a clinical study titled "Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen with or without octreotide may fight breast cancer by blocking the uptake of estrogen. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III ...
What is the current status of trial NCT00002864?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 667 participants. The study started on 1996-09-24. Estimated completion is 2010-04-23.
What interventions are being tested in trial NCT00002864?
The interventions under investigation include: tamoxifen citrate (DRUG), octreotide acetate (DRUG).
Who is sponsoring clinical trial NCT00002864?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.